Compare LOAN & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOAN | CTSO |
|---|---|---|
| Founded | 1989 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.9M | 45.7M |
| IPO Year | 1999 | 2008 |
| Metric | LOAN | CTSO |
|---|---|---|
| Price | $4.39 | $0.74 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 19.0K | ★ 62.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 10.02% | N/A |
| EPS Growth | ★ 2.08 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | $9,688,641.00 | ★ $22,503,908.00 |
| Revenue This Year | N/A | $7.29 |
| Revenue Next Year | $4.47 | $8.91 |
| P/E Ratio | $12.52 | ★ N/A |
| Revenue Growth | N/A | ★ 48.53 |
| 52 Week Low | $4.29 | $0.60 |
| 52 Week High | $6.05 | $1.39 |
| Indicator | LOAN | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 31.35 | 65.19 |
| Support Level | $4.29 | $0.61 |
| Resistance Level | $4.59 | $1.02 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 8.97 | 91.86 |
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.